oral PrEP

  • Meeting Report: Stakeholder Consultation on MTN–042

    The Microbicide Trials Network (MTN), in partnership with AVAC, held a consultation with key stakeholders in Johannesburg, South Africa, from April 5–6, 2018, to hear their views about the design and objectives of the MTN–042 study and to seek their opinions about specific aspects of the study. Held as part of the protocol development process, the consultation was timed so that stakeholder feedback could then be considered at a meeting of the team developing the MTN–042 study protocol.

  • The DELIVER and B-PROTECTED Studies: Preventing HIV in Pregnant and Breastfeeding

    Knowing whether daily oral pre-exposure prophylaxis (PrEP) and use of the monthly dapivirine ring are safe during pregnancy and breastfeeding is vitally important. This fact sheet provides background on two studies that will address these questions.

  • MTN–042 – DELIVER

    Links are provided to information about the DELIVER study, which is evaluating the safety and acceptability of the use of a monthly dapivirine ring or a daily antiretroviral pill (FTC/TDF, or Truvada) during pregnancy.

  • REACH Study (MTN–034)

    Links are provided to information about Reversing the Epidemic in Africa with Choices in HIV prevention (REACH), or MTN-034, a trial evaluating how adolescent girls and young women use the monthly dapivirine vaginal ring and oral Truvada® (FTC/TDF) as daily pre-exposure prophylaxis (PrEP). The Microbicide Trials Network is conducting this trial to gain a better understanding of the HIV prevention needs and preferences of adolescent girls and young women and to collect information on the safety of both approaches for women in these age groups.

  • REACH HIV Prevention Study in Africa (Video)

    Aimed at potential study participants, this video provides background and describes the purpose and design of the Reversing the Epidemic in Africa with Choices in HIV prevention (REACH) study, or MTN-034. REACH is an open-label trial to evaluate how adolescent girls and young women use the monthly dapivirine vaginal ring and oral Truvada® (FTC/TDF) as daily pre-exposure prophylaxis (PrEP).